AstraZeneca's treatment for fatal myocardial disease has been approved for clinical trials in China.

Astrazeneca's new drug ALXN2220 injection has obtained clinical trial implied consent in China for the treatment of diagnosed transthyretin amyloid cardiomyopathy in adult patients. ALXN2220 is a monoclonal antibody against transthyretin amyloid protein, with the potential to treat late-stage ATTR-CM patients. Alexion, a subsidiary of Astrazeneca, holds the global exclusive licensing rights for this product. The safety and efficacy of the product have been validated in preclinical models and Phase 1 clinical studies. Currently, Alexion is conducting an international multicenter Phase 3 clinical trial to evaluate the efficacy and safety of ALXN2220.